Stabilized synthetic immunogen delivery system
The present invention provides an immunostimulatory complex specifically adapted to act as adjuvant and as a peptide immunogen stabilizer. The immunostimulatory complex comprises a CpG oligonucleotide and a biologically active peptide immunogen. The immunostimulatory complex is particulate and can efficiently present peptide immunogens to the cells of the immune system to produce an immune response. The immunostimulatory complex may be formulated as a suspension for parenteral administration. The immunostimulatory complex may also be formulated in the form of w/o-emulsions or in-situ gelling polymers for the efficient delivery of immunogens to the cells of the immune system of a subject following parenteral administration, to produce an immune response.
1. A stabilized immunostimulatory microparticulate complex comprising a cationic peptide immunogen wherein the peptide immunogen comprises a target B cell antigen or a CTL epitope and a T helper cell epitope and
an anionic CpG oligonucleotide
wherein the cationic peptide immunogen has a net positive charge at a pH in the range of 5.0 to 8.0 calculated by assigning a +1 charge for each lysine (K), arginine (R) or histidine (H), a −1 charge for each aspartic acid (D) or glutamic acid (E) and a charge of 0 for all other amino acids in the peptide immunogen and
wherein the anionic CpG oligonucleotide has a net negative charge at a pH in the range of 5.0-8.0 and is a single-stranded DNA comprising 8 to 64 nucleotide bases with a repeat of a cytosine-guanidine motif and the number of repeats of the CpG motif is in the range of 1 to 10, and
wherein the cationic peptide immunogen:CpG oligonucleotide charge ratio ranges from 8:1 to 1:2 and
wherein the microparticulate complex is a precipitate with an average particle size of about 22.5 microns or less.
2. The immunostimulatory microparticulate complex of claim 1 , wherein the cationic peptide immunogen is a mixture of synthetic peptide immunogens.
3. The immunostimulatory microparticulate complex of claim 1 , wherein the net positive charge of the cationic peptide immunogen is at least +2.
4. The immunostimulatory microparticulate complex of claim 2 , wherein the average net positive charge of the mixture of synthetic peptide immunogens is at least +2.
5. The immunostimulatory microparticulate complex of claim 4 , wherein the net negative charge of the anionic oligonucleotide is at least −2.
6. The immunostimulatory microparticulate complex of claim 1 , wherein the CpG oligonucleotide is a single-stranded DNA molecules with 18-48 nucleotide bases and the number of repeats of CpG motif therein in the range of 3 to 8.
7. The immunostimulatory microparticulate complex of claim 1 , wherein the CpG oligonucleotide has the formula: 5′ X 1 CGX 2 3′ wherein C and G are unmethylated; and X 1 is selected from the group consisting of A (adenine), G (guanine) and T (thymine); and X 2 is C (cytosine) or T (thymine).
8. The immunostimulatory microparticulate complex of claim 1 , wherein CpG oligonucleotide is selected from a group consisting of 5′ TCG TCG TTT TGT CGT TTT GTC GTT TTG TCG TT 3′ (CpG1) SEQ ID NO: 1, a 32 base length oligomer, and 5′nTC GTC GTT TTG TCG TTT TGT CGT T 3′ (CpG2) SEQ ID NO: 2, a 24 base length oligomer plus an phosphorothioate group designated as n.
9. The immunostimulatory microparticulate complex of claim 8 , wherein CpG oligonucleotide is 5′ TCG TCG TTT TGT CGT TTT GTC GTT TTG TCG TT 3′ (CpG1) SEQ ID NO: 1.
10. The immunostimulatory microparticulate complex of claim 8 , wherein the cationic peptide immunogen is a synthetic peptide conjugated to a T helper cell epitope.
11. The immunostimulatory microparticulate complex of claim 10 , wherein the cationic immunogen is selected from the group consisting of SEQ ID NO: 7, 8 and 9 and a mixture thereof.
12. The immunostimulatory microparticulate complex of claim 1 , wherein the cationic peptide immunogen:CpG oligonucleotide charge ratio ranges from 4:1 to 1:1.
13. The immunostimulatory microparticulate complex of claim 1 , wherein the microparticulate complex is a precipitate with an average particle size of about 10 microns or less.
14. A stabilized immunostimulatory microparticulate complex comprising a cationic peptide immunogen wherein the peptide immunogen comprises a target B cell antigen or a CTL epitope and a T helper cell epitope and
an anionic CpG oligonucleotide
wherein the cationic peptide immunogen has a net positive charge at a pH in the range of 5.0 to 8.0 calculated by assigning a +1 charge for each lysine (K), arginine (R) or histidine (H), a −1 charge for each aspartic acid (D) or glutamic acid (E) and a charge of 0 for all other amino acids in the peptide immunogen and
wherein the anionic CpG oligonucleotide has a net negative charge at a pH in the range of 5.0-8.0 and is a single-stranded DNA comprising 8 to 64 nucleotide bases with a repeat of a cytosine-guanidine motif and the number of repeats of the CpG motif is in the range of 1 to 10, and
wherein the cationic peptide immunogen:CpG oligonucleotide charge ratio ranges from 8:1 to 1:2 and
wherein the microparticulate complex is formed by combining the CpG oligonucleotide to the cationic peptide immunogen, or vice versa, in a dropwise manner to form a precipitate with an average particle size of about 22.5 microns or less.
15. The immunostimulatory microparticulate complex of claim 14 , wherein the cationic peptide immunogen is a mixture of synthetic peptide immunogens.
16. The immunostimulatory microparticulate complex of claim 14 , wherein the net positive charge of the cationic peptide immunogen is at least +2.
17. The immunostimulatory microparticulate complex of claim 15 , wherein the average net positive charge of the mixture of synthetic peptide immunogens is at least +2.
18. The immunostimulatory microparticulate complex of claim 16 or 17 , wherein the net negative charge of the anionic oligonucleotide is at least −2.
19. The immunostimulatory microparticulate complex of claim 14 , wherein the CpG oligonucleotide is a single-stranded DNA molecules with 18-48 nucleotide bases and the number of repeats of CpG motif therein in the range of 3 to 8.
20. The immunostimulatory microparticulate complex of claim 14 , wherein the CpG oligonucleotide has the formula: 5′ X1CGX2 3′ wherein C and G are unmethylated; and X1 is selected from the group consisting of A (adenine), G (guanine) and T (thymine); and X2 is C (cytosine) or T (thymine).
21. The immunostimulatory microparticulate complex of claim 14 , wherein CpG oligonucleotide is selected from a group consisting of 5′ TCG TCG TTT TGT CGT TTT GTC GTT TTG TCG TT 3′ (CpG1) SEQ ID NO: 1, a 32 base length oligomer, and 5′nTC GTC GTT TTG TCG TTT TGT CGT T 3′ (CpG2) SEQ ID NO: 2, a 24 base length oligomer plus an phosphorothioate group designated as n.
22. The immunostimulatory microparticulate complex of claim 21 , wherein CpG oligonucleotide is 5′ TCG TCG TTT TGT CGT TTT GTC GTT TTG TCG TT 3′ (CpG1) SEQ ID NO: 1.
23. The immunostimulatory microparticulate complex of claim 21 , wherein the cationic peptide immunogen is a synthetic peptide conjugated to a T helper cell epitope.
24. The immunostimulatory microparticulate complex of claim 23 , wherein the cationic immunogen is selected from the group consisting of SEQ ID NO: 7, 8 and 9 and a mixture thereof.
25. The immunostimulatory microparticulate complex of claim 14 , wherein the cationic peptide immunogen:CpG oligonucleotide charge ratio ranges from 4:1 to 1:1.
26. The immunostimulatory microparticulate complex of claim 14 , wherein the microparticulate complex is a precipitate with an average particle size of about 10 microns or less.